The largest database of trusted experimental protocols

Quinidine

Quinidine is a naturally occurring stereoisomer of the antimalarial agent quinine.
It is used primarily as an antiarrhythmic agent to treat ventricular arrhythmias, and can also be used to treat atrial fibrillation and flutter.
Quinidine works by blocking sodium channels, resulting in a slowed conduction velocity and increased refractory period in cardiac tissue.
This helps to terminate and prevent the recurrence of abnormal heart rhythms.
Researchers can optimize their quinidine studies using PubCompare.ai's AI-driven protocol comparison tool, which allows them to easily locate and compare protocols from literature, pre-prints, and patents to find the best and most reproducible approach, streamlining their quinidine research.

Most cited protocols related to «Quinidine»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Amodiaquine Biological Assay Cells chloroquine phosphate Cytostatic Agents Ethanol Fluorescence Medical Devices Mefloquine Hydrochloride Parasite Control Parasitemia Parasites Pellets, Drug Pets Pharmaceutical Preparations Primaquine Diphosphate Protoplasm Quinidine Quinine SYBR Green I Technique, Dilution Verapamil Hydrochloride Volumes, Packed Erythrocyte

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Acetaminophen Bicarbonate, Sodium Cancellous Bone Cardioplegic Solutions Cerebral Ventricles Cold Temperature dofetilide Endocardium Fingers Glucose Heart HEPES Magnesium Chloride PACE protocol Pharmaceutical Preparations Protoplasm Pulse Rate Quinidine Sodium Chloride Sotalol Sulfoxide, Dimethyl Technique, Dilution Tissues Tyrode's solution Verapamil
This study was conducted on 50 physically active young adults (males: n = 25; females: n = 25), although data analysis was performed on 21 males and 23 females due to exclusion criteria, discussed in the statistical analysis of the data (Table 1). There were significant differences between the genders in terms of height, mass and percentage body fat, but no differences in age, body mass index, waist-to-hip ratio or weekly physical activity levels (Table 1). Participation was voluntary, and written informed consent was obtained from all participants. The study was approved by the Institution’s Biomedical Research Ethics Committee (REF: BE111/010).
Participants were excluded from the study if they had experienced a cold or feverish illness in the month leading up to the study, were smokers, had a pre-existing heart condition either current or in the past, were pregnant, diabetic, had congestive heart failure, or acute or chronic renal disease, if they have a pacemaker, or were taking type 1A anti-arrhythmics (quinidine, procainamide, disopyramide or moricizine).
Full text: Click here
Publication 2012
Anti-Arrhythmia Agents Body Fat Chronic Kidney Diseases Common Cold Congestive Heart Failure Disopyramide Ethics Committees, Research Females Fever Heart Index, Body Mass Males Moricizine Pacemaker, Artificial Cardiac Procainamide Quinidine Sex Characteristics Waist-Hip Ratio Young Adult
The RECOVERY trial is an investigator-initiated, streamlined, individually randomised, controlled, open-label, platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone,7 (link) hydroxychloroquine,21 (link) lopinavir–ritonavir,22 (link) azithromycin,23 (link) tocilizumab,9 (link) and convalescent plasma24 (link)) have been published previously. The trial is underway at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal (appendix pp 3–25). The trial is supported by the National Institute for Health Research Clinical Research Network, and is coordinated by the Nuffield Department of Population Health (University of Oxford, Oxford, UK), the trial sponsor. The trial was done in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (20/EE/0101). The protocol, statistical analysis plan, and additional information are available online.
Patients admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Children and pregnant women were not eligible to receive colchicine. Patients with severe liver impairment, significant cytopaenia, concomitant use of strong CYP3A4 (eg, clarithromycin, erythromycin, systemic azole antifungal, and HIV protease inhibitor) or P-glycoprotein inhibitors (eg, ciclosporin, verapamil, and quinidine), or hypersensitivity to lactose were excluded from the colchicine comparison (appendix p 81). Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.
Full text: Click here
Publication 2021
Antifungal Agents Azithromycin Azoles Child Clarithromycin Colchicine Conferences COVID 19 Cyclosporins Cytochrome P-450 CYP3A4 Dexamethasone Erythromycin Ethics Committees, Research HIV Protease Inhibitors Hydroxychloroquine Hypersensitivity inhibitors Lactose Liver lopinavir-ritonavir drug combination P-Glycoprotein Patients Population Health Pregnant Women Quinidine tocilizumab Verapamil
Wild-type cells or cells transgenically expressing a translational fusion of CCA1 to luciferase from the CCA1 promoter (CCA1-LUC) 10 (link) were grown under 12h/12h light/dark cycles in artificial sea water (24 g/l NaCl, 4 g/l Na2SO4, 0.68 g/l KCl, 200 mg/l NaHCO3, 100 mg/l KBr, 25 mg/l H3BO3, 3 mg/l NaF, plus hydrous salts: 50 mM MgCl2*6H2O, 10 mM CaCl2*2H2O, 0.1 µM SrCl*6H20), supplemented with Guillard's F/2 marine enrichment solution and 10 nM H2SeO3. Full medium was adjusted to a salinity of 30 ppt.
Imaging and analysis of luminescent rhythms was performed as described31 (link)–33 . For resetting experiments, magnesium-free media were removed with a multichannel pipette and replaced with magnesium-containing media. In all luminescent imaging experiments, 8 replicate wells constitute n=8, and presented experiments are representative of 3 or more replicate experiments.
For ICP-MS analyses, 30 ml culture was pelleted, washed three times in 1 M Sorbitol to remove sea water, and digested in 100 µl nitric acid (69%, ARISTAR grade, VWR International) spiked with 345 ppb indium (VWR International) at RT for ~3 hours. Samples were then diluted to a final concentration of 2% v/v nitric acid and 10 ppb Indium prior to analysis on an Agilent 7500ce with octopole reaction system. Serial dilutions of ICP-Multi-element solution IV (Merck, Certipur) was used for calibration of all the metals analysed and to check for instrument drift. A standard reference material SRM1643e (NIST) was analysed to validate the calibration. Indium was used to correct for dilution errors introduced during handling. ICP-MS data reported is based on three replicate flasks, each sampled every timepoint (n=3). Results presented have been verified in a replicate experiment, and outliers were excluded if they were >2 S.D. from the mean.
Cell extracts for luminescent Mg2+ and ATP assays were made from 3 replicates (n=3) of 5 ml cell culture, pelleted and washed with 1 M Sorbitol, and resuspended in 100 µl medium before adding 100 µl 2x extraction buffer (1% Triton X-100, 300 mM NaCl, 100 mM HEPES). 25 µl of extract was boiled and added to 75 µl of assay mix (40 mM HEPES, 1 mM luciferin, 0.05 mg/ml QuantiLum (Promega), and either 1 mM MgCl2 or 10 µM ATP). Luminescence was measured on a TopCount (Packard) plate reader against a standard curve. As Mg2+ ions that remain tightly bound to cellular macromolecules such as membrane components and DNA are not detected by this alternative assay, the relative amplitude of [Mg2+]i changes observed using this assay were substantially larger than measured by ICP-MS. Quinidine, CHA and CPA were made up in medium and added 24 hours prior to cell lysis for chronic treatments. Results were verified in one or more replicate experiments. For puromycin experiments (Fig. 4), cobalt ammines or vehicle were added at ZT6 or ZT18, and 0.5 mg/ml puromycin was added 20 minutes before harvesting cells at ZT11 and ZT23 (required concentration and incubation time determined empirically to reduce expression from a constitutive promoter driving luciferase by ~half). Analysis of incorporation was performed as described for U2OS cells below. Loading control was RbcL (Coomassie).
To identify potential Ostreococcus transporter proteins, mammalian sequences for all classes of SLC and all known magnesium transporters were blasted onto the Ostreococcus proteome using DELTA-BLAST (NCBI), and gene models were then taken from the latest version of the Ostreococcus genome 34 (link) using the Orcae service 35 (link) (Gent University).
Publication 2016
Bicarbonate, Sodium Biological Assay Buffers Carrier Proteins Cell Culture Techniques Cells Cobalt DNA Replication Genome HEPES Indium Ions Luciferases Luciferins Luminescence Magnesium Magnesium Chloride Mammals Marines Membrane Transport Proteins Metals Nitric acid Promega Protein Biosynthesis Proteome Puromycin Quinidine Salinity Salts Sodium Chloride Sorbitol Technique, Dilution Tissue, Membrane Triton X-100

Most recents protocols related to «Quinidine»

Elderly patients who underwent lower extremity arthroplasty in Drum Tower Hospital Affiliated to Nanjing University Medical School from September 2020 to March 2021 were selected and followed up for postoperative pain assessment using the numerical rating scale NRS. The elderly osteoarthritis patients selected were all caused by joint degeneration rather than fractures or necrosis caused by other reasons. They were performed operations by the same group of doctors and operation method. All patients signed informed consent and were authorized by the ethics committee of Drum Tower Hospital Affiliated to Nanjing University Medical School (Nanjing, China, No. 2019-270-02). Inclusion criteria: (1) Age ≥ 65 years old; (2) American Society of Anesthesiologists (ASA) classification II–III; (3) Patients undergoing lower extremity arthroplasty; (4) Operation duration ≥ 60 min; (5) Patients recorded in electronic medical record system; (6) Patients agreed to participate in the study and signed the informed consent. Exclusion criteria: (1) With gene deficiency disease; (2) Having history of opioid abuse; (3) Using drugs that induce or inhibit liver isoenzymes (such as carbamazepine, quinidine, ketoconazole, etc.) in 4 weeks before operation; (4) Combined with peripheral neuropathy and psychiatric history, chronic pain and long-term opioid use history; (5) With poor body conditions affecting the perioperative pain evaluation; (6) Patients can’t cooperate and communicate with.
The patient's NRS score being ≥ 4 on the 90th day after operation was identified as having severe CPSP. A total of 10 patients were judged to have severe CPSP (group A). 10 patients hospitalized in the same period without chronic postsurgical pain (NRS score = 0 on the 90th day after operation) were randomly selected as the control group (group B).
Full text: Click here
Publication 2023
Abuse, Opioid Aged Anesthesiologist Arthroplasty Carbamazepine Cardiac Arrest Chronic Pain Deficiency Diseases Degenerative Arthritides Ethics Committees, Clinical Fracture, Bone Genes Human Body Isoenzymes Ketoconazole Liver Lower Extremity Necrosis Opioids Pain Measurement Patients Peripheral Nervous System Diseases Pharmaceutical Preparations Physicians Postoperative Pain, Chronic Quinidine
To investigate the potential of BI 425809 to reversibly inhibit the major human CYPs, CYP-selective substrates (phenacetin 60 μM [CYP1A2], bupropion 80 μM [CYP2B6], amodiaquine 2 μM [CYP2C8], diclofenac 5 μM [CYP2C9], S-mephenytoin 80 μM [CYP2C19], dextromethorphan 5 μM [CYP2D6], midazolam 2 μM, and testosterone 50 μM [CYP3A4/5]) were incubated with human liver microsomes and BI 425809 (0.015, 0.046, 0.137, 0.411, 1.23, 3.70, 11.1, 33.3, and 100 μM). For positive control reactions, BI 425809 was replaced with a CYP-selective inhibitor (α-naphthoflavone [CYP1A2], ticlopidine [CYP2B6], montelukast [CYP2C8], sulfaphenazole [CYP2C9], benzylnirvanol [CYP2C19], quinidine [CYP2D6], and itraconazole [CYP3A4/5]). Substrate metabolites were quantified with liquid chromatography–tandem mass spectrometry using gradient elution (mobile phase for amodiaquine metabolite—A, 5 mM ammonium formate in water/formic acid [100:0.1, v/v]; B, acetonitrile/formic acid [100:0.1, v/v]; mobile phase for all other substrate metabolites—A, water/formic acid [100:0.1, v/v]; B, acetonitrile/formic acid [100:0.1, v/v]) on a Synergi Hydro RP column (50 × 2.0 mm, 4 μm; Phenomenex) with positive electrospray ionization.
IC50 values were obtained using a 3-parameter dose-response, 4-parameter dose-response, or normalized dose-response model; model comparisons were performed in Prism 6 (GraphPad Inc) to determine the optimal model for each data set. A least-squares fitting approach was used, and the Hill slope was not constrained for the 4-parameter model.
Publication 2023
acetonitrile Amodiaquine BI 425809 Bupropion Cardiac Arrest CYP1A2 protein, human CYP2C8 protein, human CYP2C19 protein, human Cytochrome P-450 CYP2D6 Cytochrome P-450 CYP3A4 Dextromethorphan Diclofenac formic acid formic acid, ammonium salt Homo sapiens Itraconazole Liquid Chromatography Mephenytoin Microsomes, Liver Midazolam montelukast Phenacetin prisma Quinidine Sulfaphenazole Tandem Mass Spectrometry Testosterone Ticlopidine
The collection time of the plasma sample included data from before administration of bepridil to up to 6 h after administration. To assess risk factors for achieving plasma bepridil concentrations ≥800 ng/mL at steady state, the eligible patients were divided into two groups based on their bepridil concentrations: ≥800 ng/mL and < 800 ng/mL.
The C/D ratio was calculated using the following equation:
C/D ratio of bepridil = plasma concentration of bepridil (ng/mL) / dose of bepridil (mg/day/kg body weight).
In this study, we defined the polypharmacy group as those who use six or more drugs, whereas the non-polypharmacy group was those who took fewer than six drugs. The relationship between plasma bepridil concentrations ≥800 ng/mL and baseline characteristics, including sex, age, height, body weight, body mass index, serum creatinine, creatinine clearance (Ccr), number of concomitant drugs used, typical inducers of CYPs (phenytoin, carbamazepine, phenobarbital, and rifampicin) [15 (link)], typical inhibitors of CYPs (erythromycin, clarithromycin, protease inhibitors, and azole antifungals) [15 (link)], aprindine, a competitive inhibitor of CYP2D6 [12 (link)], typical inhibitor of P-gp (amiodarone, diltiazem, nicardipine, nifedipine, propranolol, quinidine, cyclosporin, and tacrolimus) [16 (link)–18 (link)], and left ventricular ejection fraction (LVEF), were examined. LVEF was measured using echocardiographic equipment provided at each hospital. Ccr was estimated using the Cockcroft–Gault formula [19 (link)].
The patient’s medical history and duration of bepridil treatment were collected from medical records.
Full text: Click here
Publication 2023
Amiodarone Antifungal Agents Aprindine Azoles Bepridil Body Weight Carbamazepine Clarithromycin Creatinine Cyclosporine Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P450 Diltiazem Echocardiography Erythromycin Index, Body Mass inhibitors Nicardipine Nifedipine Patients Pharmaceutical Preparations Phenobarbital Phenytoin Plasma Polypharmacy Propranolol Protease Inhibitors Quinidine Rifampin Serum Specimen Collection Tacrolimus Ventricular Ejection Fraction
The experiments were classified into six groups (n = 3): control (no inhibitor), positive inhibitor, SZ-A (final concentration, 8.899 μg/mL; equivalent to 20 μM DNJ), DNJ (final concentration, 20 μM), FA (final concentration, 5 μM), and DAB (final concentration, 8 μM). Different inhibitors were added to the HLMs/RLMs and incubated with the probe substrates of each subtype.
The liver microsomal incubation system comprised human or rat liver microsomal protein (0.5 mg/mL), nicotinamide adenine dinucleotide phosphate (NADPH) generation system, Tris-HCl buffer (50 mM, pH 7.4), substrate, and inhibitor, with a total reaction volume of 200 μL. The substrate concentrations and incubation times for CYP1A2, 2D6/2D2, 2C9/2C6, 2C19/2C11, 3A4/3A2, and 2E1 were phenacetins, 50 μM/30 min; dextromethorphan, 5 μM/10 min; diclofenac sodium, 20 μM/10 min; mephenytoin, 40 μM/30 min; midazolam, 5 μM/5 min; and chlorzoxazone, 80 μM/20 min, respectively. The concentrations of each isoenzyme-positive inhibitor were 10 μM of furafylline (50 μM in the rat group), 2 μM quinidine (25 μM in the rat group), 5 μM sulfaphenazole (50 μM in the rat group), 5 μM of diclofenac pyridine (25 μM in the rat group), 1 μM ketoconazole, and 80 μM sodium diethyldithiacarbamate (100 μM in the rat group). After the reaction was completed, 400 μL of the internal standard propranolol (final concentration, 200 ng/mL) in ice-cold acetonitrile was added to terminate the reaction, and the sample was mixed well and centrifuged twice at 14,000 rpm for 5 min. Five microliters of the supernatant were collected for LC-MS/MS analysis (UPLC-Q-Extractive Orbitrap MS; Thermo Fisher Scientific, Waltham, MA, United States) to determine the metabolite content of the probe substrate.
Full text: Click here
Publication 2023
acetonitrile Chlorzoxazone Cold Temperature Cytochrome P-450 CYP1A2 Dextromethorphan Diclofenac Diclofenac Sodium Exhaling furafylline inhibitors Isoenzymes Ketoconazole Mephenytoin Microsomes Microsomes, Liver Midazolam NADP NR4A2 protein, human Portal System Propranolol pyridine Quinidine Sodium Sulfaphenazole Tandem Mass Spectrometry Tromethamine
DNJ (purity >99.0%) and SZ-A extract (Lot No.: J202004007, containing 36.88% of DNJ, 8.78% of FA, and 5.83% of DAB; Lot No.: J202108007, containing 36.52% of DNJ, 9.60% of FA, and 7.62% of DAB) were provided by Beijing Wehand-bio Pharmaceutical Co. Ltd. (Beijing, China). The multiple reaction monitoring (MRM) chromatogram of SZ-A is shown in Supplementary Figure S1. Miglitol was obtained from TCI Shanghai Chemical Industrial Development Co., Ltd. (Shanghai, China). FA (purity >98.0%) was purchased from MedChemExpress (Monmouth Junction, NJ, United States ). DAB (purity >98.0%) was purchased from Sigma-Aldrich (St. Louis, MO, United States ). Human liver microsomes (HLMs) were purchased from Reid Liver Disease Research (Shanghai, China). Glucose-6-phosphate, oxidized coenzyme H (β-NADP), Glucose-6-phosphate dehydrogenase, midazolam, phenacetin, dextromethorphan, mephenytoin, chlorzoxazone, diclofenac sodium, 1-Hydroxy-midazolam, 4-hydroxy-mephenytoin, acetaminophen, 4-Hydroxy-diclofenac sodium, demethyldextromethorphan, 6-Hydroxy-chlorzoxazone, furaphylline, sulfafenpyrazole, quinidine, ketoconazole, and sodium diethyldithiacarbamate were purchased from Sigma-Aldrich (St. Louis, MO, United States ). All other organic reagents were of analytical grade and purchased from Sinopharm Chemical Reagent (Shanghai, China).
Full text: Click here
Publication 2023
4'-hydroxydiclofenac Acetaminophen Chlorzoxazone Coenzymes Dextromethorphan Diclofenac Sodium Glucose-6-Phosphate Glucosephosphate Dehydrogenase Hepatobiliary Disorder Homo sapiens Ketoconazole Mephenytoin Microsomes, Liver Midazolam miglitol NADP Pharmaceutical Preparations Phenacetin Quinidine Sodium

Top products related to «Quinidine»

Sourced in United States, Germany, China, Japan, France
Quinidine is a pharmaceutical compound used as a laboratory reagent. It is a diastereomer of the alkaloid quinine and has a chemical structure that allows it to be used in various biochemical and analytical applications.
Sourced in United States, China, Germany
Sulfaphenazole is a laboratory reagent used in chemical synthesis and analysis. It is a sulfonamide compound with molecular formula C₁₄H₁₁N₃O₂S. Sulfaphenazole is commonly used as an analytical standard and in various organic reactions.
Sourced in United States, Germany, India, Sao Tome and Principe, United Kingdom, Macao, Israel
Ketoconazole is a laboratory product manufactured by Merck Group. It is an antifungal agent used for research and development purposes. The core function of Ketoconazole is to inhibit the synthesis of ergosterol, a key component of fungal cell membranes.
Sourced in United States, China
Furafylline is a laboratory compound used as a research tool. It is a selective inhibitor of the CYP1A2 enzyme, which is involved in the metabolism of various drugs and other substances. Furafylline is utilized in studies to investigate the role of CYP1A2 in drug interactions and pharmacokinetics.
Sourced in United States, China, Germany, United Kingdom, Poland
Phenacetin is a chemical compound used in the manufacturing of various pharmaceutical and laboratory products. It serves as a key ingredient in the production process. Phenacetin has specific functional properties that make it a valuable component in relevant applications, but a detailed description of its core function is beyond the scope of this response.
Sourced in United States, China, Germany, United Kingdom, Czechia
Chlorzoxazone is a laboratory chemical used as a reference standard. It is a crystalline solid with a molecular formula of C7H5ClNO. Chlorzoxazone is primarily used for analytical purposes and quality control in various industries.
Sourced in United States, Germany, China, Canada, Macao, Australia, Sao Tome and Principe
Glucose-6-phosphate dehydrogenase is an enzyme that catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone, the first step of the pentose phosphate pathway. This enzyme plays a crucial role in maintaining cellular redox balance and generating NADPH, which is essential for various cellular processes.
Sourced in United States, Germany, China, United Kingdom, Canada, Italy, Japan, Switzerland, France
Acetaminophen is a chemical compound used in the production of various pharmaceutical and laboratory products. It is a white, crystalline solid that is soluble in water and alcohol. Acetaminophen is a common active ingredient in over-the-counter pain and fever-reducing medications.
Sourced in United States, China, Germany
7-hydroxycoumarin is a chemical compound used as a laboratory reagent. It is a naturally occurring coumarin derivative that can be utilized in various analytical and research applications.
Sourced in China, United States
Clomethiazole is a laboratory product manufactured by Merck Group. It is a chemical compound used in various research and analytical applications. The core function of Clomethiazole is to serve as a research tool, without interpretation or extrapolation on its intended use.

More about "Quinidine"

Quinidine, a naturally occurring stereoisomer of the antimalarial agent quinine, is primarily used as an antiarrhythmic medication to treat ventricular arrhythmias, as well as atrial fibrillation and flutter.
This alkaloid compound works by blocking sodium channels in cardiac tissue, which slows conduction velocity and increases the refractory period, helping to terminate and prevent the recurrence of abnormal heart rhythms.
Researchers can optimize their quinidine studies using PubCompare.ai's AI-driven protocol comparison tool, which allows them to easily locate and compare protocols from literature, pre-prints, and patents.
This helps researchers find the best and most reproducible approach, streamlining their quinidine research.
Related compounds, such as sulfaphenazole, ketoconazole, furafylline, phenacetin, chlorzoxazone, and glucose-6-phosphate dehydrogenase, can also play a role in quinidine metabolism and interactions.
Understanding the interplay between these substances and quinidine can be crucial for developing effective and safe treatment strategies.
Additionally, the metabolites of quinidine, such as 7-hydroxycoumarin, and other compounds like acetaminophen and clomethiazole, may also be of interest in quinidine research.
By considering the broader context of quinidine's pharmacology and metabolism, researchers can gain deeper insights and optimize their investigations.
Leveraging the power of PubCompare.ai's protocol comparison tool and keeping a holistic view of quinidine's relationships with related substances can help streamline and enhance the quality of quinidine research, leading to more effective and reproducible findings.